1,029 filings
Page 20 of 52
CORRESP
qfxpshhfldw49d4
6 Mar 19
Correspondence with SEC
12:00am
8-K
249blq6gtikks nlpj5
4 Mar 19
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
bfa2ifmycvmqpdlj43d
28 Feb 19
Trovagene to Present Data from Lead Clinical Programs of Onvansertib in AML and mCRPC
10:38am
UPLOAD
hoc9biqo4ybghi5onv
25 Feb 19
Letter from SEC
12:00am
8-K
rj4p9r35yl5clqokxfjd
20 Feb 19
Trovagene, Inc. Announces Reverse Stock Split
10:04am
8-K
lom3hn01 2km11kw
14 Feb 19
Trovagene Presents Update on Phase 2 Study of Onvansertib in Combination with Zytiga in Patients with mCRPC atASCO-GU Conference
10:43am
SC 13G/A
n6deg6j5b1udj3ks
12 Feb 19
Trovagene, Inc.
5:01pm
8-K
5eb8ejxtlvvtoia1nqkf
12 Feb 19
Submission of Matters to a Vote of Security Holders
4:17pm
8-K
3666pao8j
31 Jan 19
Amendments to Articles of Incorporation or Bylaws
4:56pm
DEFA14A
0cmica
31 Jan 19
Additional proxy soliciting materials
4:54pm
8-K
09tc y3w590oc
29 Jan 19
Entry into a Material Definitive Agreement
5:23pm
8-K
3skj4mdpyjbks118odmg
23 Jan 19
Trovagene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to TreatNon-Metastatic and Metastatic Prostate Cancer
8:44am
8-K
175wtyhesz 2w
15 Jan 19
Other Events
4:57pm
DEFA14A
dhrj5tt0s3y5f9r
15 Jan 19
Additional proxy soliciting materials
4:55pm
4
e54kegq42d9 t84frt
4 Jan 19
Trovagene / Mark Erlander ownership change
4:10pm
4
qndgtn 4r
4 Jan 19
Trovagene / Mark Erlander ownership change
4:05pm
8-K
dy63llv
14 Dec 18
Departure of Directors or Certain Officers
4:30pm